Alliance Global raised the firm’s price target on Reviva Pharmaceuticals (RVPH) to $30 from $16 and keeps a Buy rating on the shares. Reviva Pharmaceuticals reported Q4 and full-year 2025 results, outlining plans to initiate the Phase 3 RECOVER-2 trial of brilaroxazine for schizophrenia in mid-2026 following FDA alignment at a pre-NDA meeting and completion of RECOVER-1, the analyst tells investors in a research note. With additional pre-NDA studies and manufacturing completed, the company is positioning for an upcoming NDA submission while expanding clinical visibility through recent and planned data publications, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- RVPH Earnings this Week: How Will it Perform?
- Reviva Pharmaceuticals Announces $10 Million Equity Offering
- Reviva Pharmaceuticals prices $10M public offering at $1.50 per share
- Reviva Pharmaceuticals announces common stock, warrants offering
- Upcoming Stock Splits This Week (March 9 to March 13) – Stay Invested